Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The purchase, described as adding roughly 38,000 shares, is the latest example of executive insider activity tied to Pfizer’s stock
THE APEX TIMES
THE APEX TIMES
The company has reached a settlement tied to Chantix, a smoking-cessation medicine, with payouts potentially available to eligible claimants. A notice points readers to the claim process and filing timeframe.
THE APEX TIMES
A fresh comparison frames Pfizer and AbbVie as income-focused options for 2026, pointing to their dividend levels as a key differentiator versus the broader market.
THE APEX TIMES
Management told investors that growth outside COVID-19 increased and reiterated a large cost-reduction goal, while offering an updated guidance framework on its Q2 2026 earnings call.
THE APEX TIMES
A new comparison of Pfizer and BioNTech, two firms tied to the COVID-19 vaccine partnership, points to a shared challenge: how to sustain growth as pandemic-era demand fades. The article discusses their Q2 2026 earnings and highlights major strategic announcements, but does not provide enough detail to determine which company has the clearer path forward.
THE APEX TIMES
A reported 6.4% dividend yield is attracting income-focused investors, but the latest performance concerns suggest investors may be recalibrating expectations for future payouts.
THE APEX TIMES
Pfizer reported a second-quarter beat and lifted its 2026 revenue outlook, sending shares up sharply. The backdrop remains challenging, with declining COVID-19 revenue and pressure from patent-related losses.
THE APEX TIMES
The new report, distributed via a GlobeNewswire announcement syndicated on Yahoo Finance, examines the global influenza vaccine market and includes company profiles of Pfizer, GSK, Sanofi and Moderna.
THE APEX TIMES
A market-focused post following second-quarter results frames the choice for income-seeking investors as a trade-off between Pfizer’s shareholder payout profile and Merck’s efforts to fund the next growth phase through acquisitions or licensing-style investments.
